Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2013

Coffee Erin M, Faber Anthony C, Roper Jatin, Sinnamon Mark J, Goel Gautam, Keung Lily, Wang Wei Vivian, Vecchione Loredana, de Vriendt Veerle, Weinstein Barbara J, Bronson Roderick T, Tejpar Sabine, Xavier Ramnik J, Engelman Jeffrey A, Martin Eric S, Hung Kenneth E

Abstract excerpt

PURPOSE: BRAF(V600E) mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Although selective BRAF inhibitors are effective for treatment of melanoma, comparable efforts in CRC have been disappointing. Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAF(V600E) CRC. EXPERIMENTAL DESIGN: We examined phosphoinositide 3-kinase (PI3K)/mTOR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HCT116 Cells
Share to Indenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms, Experimental

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Pyrazoles

Share to TOR Serine-Threonine Kinases

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 23549875
DOI: 10.1158/1078-0432.CCR-12-2556
PMCID: PMC3815598

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.PMID 23549875Read ↗

A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention.Semantic proximity Read ↗

Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants.Semantic proximity Read ↗

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.Semantic proximity Read ↗

WNT-driven immune evasion promotes malignant transformation of <i>BRAF</i> -mutant colorectal cancerSemantic proximity Read ↗

New therapeutic strategies for BRAF mutant colorectal cancers.Semantic proximity Read ↗

The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancerSemantic proximity Read ↗

PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine.Semantic proximity Read ↗

Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.Semantic proximity Read ↗

Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasiaSemantic proximity Read ↗

Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.Semantic proximity Read ↗

Mouse models for BRAF-induced cancers.Semantic proximity Read ↗

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.